Chromosome 22q11.2 Deletion SyndromeNCT00161109
Genetics and Psychopathology in the 22q11 Deletion Syndrome
An observational study of Chromosome 22q11.2 Deletion Syndrome, run by UMC Utrecht at 2 sites in 2 countries.
Trial summary
The purposes of this study are to: 1. study the nature and longitudinal course of psychiatric symptoms in children with the 22q11.2 deletion syndrome and 2. identify genes that contribute to the occurrence of these symptoms. Read more about this study
- Who is it for?
- Ages 8 to 20 yearsHealthy volunteers can take part
- Conditions the study is for
- Chromosome 22q11.2 Deletion Syndrome
- How many people
- 175 participants
- Where
- 2 sitesin 2 countries
- Study dates
- Oct 2002to Oct 2012
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 8 to 20 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- 22q11.2 deletion confirmed with fluorescence in-situ hybridization (FISH)
Who cannot join
- None
Trial locations and contacts
2 sites in 2 countries.
2 sites in 2 countries
United States1 site, 1 recruiting
- Recruiting
Children's Hospital of Philadelphia, Dpt of Genetics and Dpt of Child and Adolescent Psychiatry
Philadelphia, Pennsylvania, 19104
Jacob AS Vorstman, M.D., 215-590-2862, vorstman@email.chop.edu
Netherlands1 site, 1 recruiting
- Recruiting
UMC Utrecht, Dpt of Child and Adolescent Psychiatry
Utrecht, 3508 GA
Herman van Engeland, M.D., Ph.D., +31 30 2506362, H.HaismaPieterse@umcutrecht.nl
About this study
The purposes of this study are to:
- study the nature and longitudinal course of psychiatric symptoms in children with the 22q11.2 deletion syndrome and
- identify genes that contribute to the occurrence of these symptoms.
Read the detailed description
The study of genes that are implicated in various mental diseases is increasingly relevant. The association between a gene and a disease can provide valuable information on how the neurobiology of the brain is altered, by studying the function of the protein encoded by the gene. This information is important for the development of new treatments.
However, the identification of these "disease" genes is difficult, due to the complexity of human behavior and the interaction of multiple genes. Moreover, the human genome consists of approximately 35,000 genes, further complicating the matter.
The situation is simplified when a psychiatric disorder and a genetic anomaly co-occur; assuming a causative relation, one can focus on the implicated genetic region.
The 22q11-deletion syndrome (22q11DS) is an example of this type; this syndrome is caused by a disappearance ("deletion") of 20-30 genes in a well-defined region on chromosome 22. People with 22q11DS have a high risk of autism and psychosis, therefore one or more genes in the 22q11DS region must be associated with these disorders.
In this study we aim to identify these genes, by carefully studying psychiatric symptoms (and additional parameters of brain functioning) in a large sample of 22q11DS children and subsequently statistically correlate these findings to specific genes within the 22q11DS region. If genes associated with autism and/or psychosis in the 22q11DS population can be found, they may help to understand the underlying neurobiology that cause these diseases, not only in 22q11DS patients but in the general population as well.
The aims of this study are:
- STUDY NATURE AND DEVELOPMENTAL COURSE OF PSYCHIATRIC SYMPTOMS. To perform a prospective longitudinal follow up study of a sample of children with the 22q11.2 deletion syndrome with specific attention to a) possible predictors for psychosis in psychiatric and neuropsychological profile and b) a possible correlation between autistic symptoms and psychosis.
- ASSESS THE CORRELATION OF 22q11.2 DELETIONS WITH THE PSYCHOSIS / AUTISTIC PHENOTYPE AND ASSOCIATED ENDOPHENOTYPES: To evaluate whether the size of the deletion and / or polymorphisms at selected candidate genes within the 22q11.2 deleted region contribute to the psychosis and or autistic phenotype or to related psychophysiologic / neuropsychological impairments in 22q11DS.
METHODS.
With regard to aim 1:
A large sample (a final sample size of 100-120 is anticipated) of children with 22q11DS, aged 10 - 20 year, is broadly phenotyped using standard psychiatric assessment methods, intelligence and selected neuropsychological tests as well as psychophysiological assessments. Approximately 4 years after the initial assessment a follow up assessment is planned. Age and IQ matched children without the deletion (or any other apparent genetic abnormality) are used as a control group.
With regard to aim 2:
- Phenotypes: Individuals with a certain endophenotype ("cases" e.g. the presence of autistic symptoms or a decreased Pre Pulse Inhibition or impaired performance on executive tasks) will be compared to children without that particular phenotype ("controls").
- Genetic analysis:
- Genotyping consists of:
- assessment of the size of the deletion and
- genotyping single nucleotide polymorphisms (SNPs) across the deleted genomic region. Genotyping will be performed using approximately 75 previously characterized SNPs, with an increased density of SNPs in the target candidate genes (~3-5 SNPs per candidate gene). In order to determine whether a haplotype and/or variants of genes within region 22q11.2 contribute to the autistic phenotype and related neuro-psychological impairments in patients with the deletion, we will identify DNA polymorphisms using existing databases. We will then genotype patients with the 22q11.2 deletion for the selected polymorphisms and compare the allele frequencies and haplotype combinations in 22q11DS patients with the phenotype ("cases") to those deleted patients without these findings ("controls") applying chi-square, Fisher's exact test, and other statistical genetic methods as appropriate.
- Conditions
- Chromosome 22q11.2 Deletion Syndrome
- Keywords
- 22q11.2 deletion syndrome, Psychopathology, Psychiatry, Neuropsychology, Psychiophysiology, Autism, Psychosis, Deletion size, Candidate genes, Psychiatric symptoms, Neuropsychological impairments, Psychophysiological performance
- Medical subject headings
- DiGeorge Syndrome, Autistic Disorder, Psychotic Disorders
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Sep 2005 (estimated)
- Study startOct 2002
- Study completionOct 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chromosome 22q11.2 Deletion SyndromeStudies of the same condition, open and under way.
- More trials run by UMC UtrechtThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Defined population
- Time perspective
- Prospective
- Enrolment
- 175 participants
Sponsor and investigators
- Lead sponsor
- UMC Utrecht
- Sponsor type
- University, hospital or other
- Collaborators
- Netherlands Brain Foundation, Children's Hospital of Philadelphia
- Investigators
- René S. Kahn, M.D., Ph.D., Study director, UMC Utrecht, The Netherlands
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00161109
- Sponsor's protocol ID
- P03.0377C
- Status last verified
- Oct 2004
- First submitted
- 8 Sep 2005
- Last updated
- 13 Oct 2006
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2006. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Genetics and Psychopathology in the 22q11 Deletion Syndrome
- ClinicalTrials.gov ID
- NCT00161109
- Acronym / sponsor ID
- P03.0377C
- Conditions
- Chromosome 22q11.2 Deletion Syndrome
- Keywords
- 22q11.2 deletion syndrome, Psychopathology, Psychiatry, Neuropsychology, Psychiophysiology, Autism, Psychosis, Deletion size
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 175 participants
- Lead sponsor
- UMC UtrechtUniversity, hospital or other
- Collaborators
- Netherlands Brain Foundation, Children's Hospital of Philadelphia
- Study start
- Oct 2002
- Study completion
- Oct 2012
- First posted
- 12 Sep 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purposes of this study are to:
- study the nature and longitudinal course of psychiatric symptoms in children with the 22q11.2 deletion syndrome and
- identify genes that contribute to the occurrence of these symptoms.
Detailed description
The study of genes that are implicated in various mental diseases is increasingly relevant. The association between a gene and a disease can provide valuable information on how the neurobiology of the brain is altered, by studying the function of the protein encoded by the gene. This information is important for the development of new treatments.
However, the identification of these "disease" genes is difficult, due to the complexity of human behavior and the interaction of multiple genes. Moreover, the human genome consists of approximately 35,000 genes, further complicating the matter.
The situation is simplified when a psychiatric disorder and a genetic anomaly co-occur; assuming a causative relation, one can focus on the implicated genetic region.
The 22q11-deletion syndrome (22q11DS) is an example of this type; this syndrome is caused by a disappearance ("deletion") of 20-30 genes in a well-defined region on chromosome 22. People with 22q11DS have a high risk of autism and psychosis, therefore one or more genes in the 22q11DS region must be associated with these disorders.
In this study we aim to identify these genes, by carefully studying psychiatric symptoms (and additional parameters of brain functioning) in a large sample of 22q11DS children and subsequently statistically correlate these findings to specific genes within the 22q11DS region. If genes associated with autism and/or psychosis in the 22q11DS population can be found, they may help to understand the underlying neurobiology that cause these diseases, not only in 22q11DS patients but in the general population as well.
The aims of this study are:
- STUDY NATURE AND DEVELOPMENTAL COURSE OF PSYCHIATRIC SYMPTOMS. To perform a prospective longitudinal follow up study of a sample of children with the 22q11.2 deletion syndrome with specific attention to a) possible predictors for psychosis in psychiatric and neuropsychological profile and b) a possible correlation between autistic symptoms and psychosis.
- ASSESS THE CORRELATION OF 22q11.2 DELETIONS WITH THE PSYCHOSIS / AUTISTIC PHENOTYPE AND ASSOCIATED ENDOPHENOTYPES: To evaluate whether the size of the deletion and / or polymorphisms at selected candidate genes within the 22q11.2 deleted region contribute to the psychosis and or autistic phenotype or to related psychophysiologic / neuropsychological impairments in 22q11DS.
METHODS.
With regard to aim 1:
A large sample (a final sample size of 100-120 is anticipated) of children with 22q11DS, aged 10 - 20 year, is broadly phenotyped using standard psychiatric assessment methods, intelligence and selected neuropsychological tests as well as psychophysiological assessments. Approximately 4 years after the initial assessment a follow up assessment is planned. Age and IQ matched children without the deletion (or any other apparent genetic abnormality) are used as a control group.
With regard to aim 2:
- Phenotypes: Individuals with a certain endophenotype ("cases" e.g. the presence of autistic symptoms or a decreased Pre Pulse Inhibition or impaired performance on executive tasks) will be compared to children without that particular phenotype ("controls").
- Genetic analysis:
- Genotyping consists of:
- assessment of the size of the deletion and
- genotyping single nucleotide polymorphisms (SNPs) across the deleted genomic region. Genotyping will be performed using approximately 75 previously characterized SNPs, with an increased density of SNPs in the target candidate genes (~3-5 SNPs per candidate gene). In order to determine whether a haplotype and/or variants of genes within region 22q11.2 contribute to the autistic phenotype and related neuro-psychological impairments in patients with the deletion, we will identify DNA polymorphisms using existing databases. We will then genotype patients with the 22q11.2 deletion for the selected polymorphisms and compare the allele frequencies and haplotype combinations in 22q11DS patients with the phenotype ("cases") to those deleted patients without these findings ("controls") applying chi-square, Fisher's exact test, and other statistical genetic methods as appropriate.
Study design
- Observational model
- Defined population
- Time perspective
- Prospective
Who may qualify
- Ages
- 8 to 20 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (1 listed)
- 22q11.2 deletion confirmed with fluorescence in-situ hybridization (FISH)
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2006.
Related trials for Chromosome 22q11.2 Deletion Syndrome
RecruitingObservational study
The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment
Pregnant Individuals, Aneuploidy
Enrolling by invitation
Parent and Infant Inter(X)Action Intervention (PIXI)
Fragile X Syndrome, Angelman Syndrome
RecruitingObservational study
Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders
Neurodevelopmental Disorders, Neurodevelopmental Disorders (NDD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
René S. Kahn, M.D., Ph.D. study director
UMC Utrecht, The Netherlands
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chromosome 22q11.2 Deletion Syndrome, run by UMC Utrecht at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 13 Oct 2006. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States, Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Jacob AS Vorstman, M.D. (215 590 3863, J.A.S.Vorstman@azu.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2006; AzTrials last refreshed its copy on 8 Nov 2026.